IGC
IGC Pharma, Inc.
Key Financials
Net Income
$-7122000
↑ 45.2%
Gross Profit
$619000
↓ 15.6%
Operating Income
$-7446000
↑ 24.0%
Total Liabilities
$2.4M
↓ 6.4%
Total Assets
$8.7M
↓ 11.7%
Shareholders' Equity
$6.3M
↓ 13.5%
Revenue
$1.3M
↓ 5.5%
EPS (Diluted)
$-0.09
↑ 59.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/6/2026 | View on SEC |
| 4 | 4/6/2026 | View on SEC |
| 4 | 4/6/2026 | View on SEC |
| 4 | 4/6/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 10-KT | 3/18/2026 | View on SEC |
| 8-K | 3/12/2026 | View on SEC |
| 4 | 2/4/2026 | View on SEC |
| 4 | 1/20/2026 | View on SEC |
| 8-K | 1/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IGC |
| Company Name | IGC Pharma, Inc. |
| CIK | 1326205 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | MD |
| Phone | 301-529-4996 |